Quarterly report [Sections 13 or 15(d)]

Condensed Statements of Operations (Unaudited)

v3.25.3
Condensed Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Income Statement [Abstract]        
Revenues
Operating Expenses:        
Research and development 634,000 1,307,000 2,096,000 3,868,000
Selling, general and administrative (including $379,000 and $0 of stock compensation for the three months ended September 30, 2025 and 2024, respectively, and $386,000 and $222,000 of stock compensation for the nine months ended September 30, 2025 and 2024, respectively) 2,748,000 2,297,000 4,731,000 6,733,000
Loss from Operations (3,382,000) (3,604,000) (6,827,000) (10,601,000)
Other Income (Expense)        
Interest income 36,000 96,000 106,000 343,000
Change in fair value of warrant liability 232,000 95,000 244,000 870,000
Gain on settlement of vendor payable 998,000
Other income 156,000
Unrealized gain on short-term investments 2,000 1,000
Total Other Income (Expense), Net 268,000 193,000 1,504,000 1,214,000
Net Loss (3,114,000) (3,411,000) (5,323,000) (9,387,000)
Dividends on preferred stock (144,000) (229,000)
Net Loss attributable to common stockholders’ $ (3,258,000) $ (3,411,000) $ (5,552,000) $ (9,387,000)
Net Loss Per Share - Basic $ (0.83) $ (1.53) $ (1.84) $ (5.28)
Net Loss Per Share - Diluted $ (0.83) $ (1.53) $ (1.84) $ (5.28)
Weighted average common shares outstanding - basic 3,940,714 2,234,328 3,025,033 1,777,313
Weighted average common shares outstanding - diluted 3,940,714 2,234,328 3,025,033 1,777,313